Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • ROOMS:

Mirati Therapeutics To Present At Upcoming Healthcare Conferences

SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences.

  • Friday, February 26th at 12:00 p.m. EST/9:00 a.m. PST at the 10th Annual SVB Leerink Global Healthcare Conference. Dan Faga, executive vice president and chief operating officer will represent Mirati in a fireside chat at the conference.
  • Wednesday, March 3rd at 2:00 p.m. EST/11:00 a.m. PST at the 41st Annual Cowen Healthcare Conference. Charles M. Baum, M.D., Ph.D., president and chief executive officer will represent Mirati in a fireside chat at the conference.

The webcast will be available through the "Investors" section of the Mirati website, Mirati Investor Events and Presentations, and a replay of the webcast will be made available for 90 days following the event.

About Mirati Therapeutics 

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of cancer patients and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer.  Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies.  Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer. 

For more information about Mirati Therapeutics, visit us at or follow us on LinkedIn.   

Logo (PRNewsfoto/Mirati Therapeutics, Inc.)


Cision View original content to download multimedia:

SOURCE Mirati Therapeutics, Inc.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.